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Abstract
Background: To study the specific antibody response to infection with Mycoplasma mycoides subsp. mycoides
Small Colony (MmmSC), the agent of Contagious Bovine Pleuropneumonia (CBPP), we examined three panels of
sera collected during three experimental infection trials in African cattle. The methods used included an in-house
complement fixation test (CFT), a commercially available CFT, a competitive antibody ELISA (cELISA) and the
immunoblotting test (IBT). In addition, lung tissue samples were examined by culture.
Results: A total of 89% (51/59) of all experimentally infected animals tested positive on at least one of the
serological tests throughout the trial. The specific antibody titres to the MmmSC infection became positive first by
CFT (6 to 9 days post infection [dpi]), followed by IBT (9 to 13 dpi) and cELISA (13 to 16 dpi). Individual animals
were found to display remarkably distinct seroconversion patterns, which allowed their classification into i) early
high responders, ii) late high responders, and iii) low responders. In accordance with other studies, none of the
present serological tests was capable of detecting all CBPP infected animals.
Conclusion: Comparison of the assays’ performance in terms of sensitivity and specificity raises serious questions
as to their reliability for identification of infected individuals in the field. In view of these limitations, a combination
of CFT and cELISA can markedly improve CBPP diagnosis at single-animal level.
Background
Contagious Bovine Pleuropneumonia (CBPP) caused by
Mycoplasma mycoides subsp. mycoides Small Colony
(MmmSC), is a highly contagious respiratory disease
notifiable to the World Organization for Animal Health
(Office International des Epizooties, OIE). While the dis-
ease is an immediate threat to livestock producers in the
endemic regions of Africa, its implications in terms of
epidemiology and animal health affect other geographi-
cal areas as well. Characteristic symptoms include anor-
exia, fever and respiratory signs, such as dyspnoea,
polypnoea, cough and nasal discharge. In Africa, the dis-
ease has been spreading due to economic, climatic and
political factors, and the limitations of currently avail-
able diagnostic tests have often been detrimental to effi-
cient control efforts. As for Europe, which has been free
of the disease since 1999 [1], the risk of CBPP re-intro-
duction through clinically inconspicuous carrier animals
is still existing and deserves permanent attention of tra-
ders and importers in the face of intensive international
trade in live cattle.
Despite their known limitations, serological methods
are still the first choice for herd diagnosis of CBPP, with
the complement fixation test (CFT) and a competitive
enzyme-linked immunosorbent assay (cELISA) being
listed as official methods in the OIE Manual [2].
The CFT, first described in 1953 [3], is widely used in
countries struggling with the disease, and a modified
“micro method” is common in countries of the Eur-
opean Union [2]. It is assumed that some of the CFT’s
drawback in terms of specificity can be overcome by
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which has been recommended by the OIE [2] as an
alternative in case of ambiguous results from CFT or
ELISA, was shown to be highly specific and sensitive [5].
Furthermore, according to OIE recommendations, sus-
pected CBPP cases identified by serology should be con-
firmed by specific detection of the pathogen. While
culture is a cumbersome and time-consuming procedure
requiring fresh tissue samples, PCR allows specific iden-
tification of the pathogen within hours. High sensitivity
is characteristic for optimised PCR assays, with detec-
tion limits between 10 [6] and 100 colony-forming units
[7]. More recently, several real-time PCR assays for
MmmSC were described [8-12]. However, if used for
herd diagnosis, PCR-based tests have their limitations
due to intermittent shedding of the pathogen, restricted
access to mycoplasmas in sequestra and the absence of
adequate equipment outside central laboratories.
Apart from the ongoing discussion on the choice of the
diagnostic test, the time course and dynamics of the spe-
cific antibody response in infected animals is not well
documented. In a typical clinical case, the major patholo-
gical consequence of MmmSC infection is a massive
inflammatory reaction mainly restricted to the lungs of
the affected animal [13], which is associated with a rise in
specific antibodies. However, it was mentioned that indi-
vidual animals respond rather differently to challenge
infection and vaccination [14-16], thus suggesting differ-
ent immune response patterns. In addition, the existence
of symptomless carriers in the field is known, some of
which may be in the sub-acute or chronic phase of infec-
tion presenting low titres or none at all [17].
It was the aim of the present study to monitor sero-
conversion of cattle experimentally challenged with
MmmSC. For this purpose, we compared the results
from four serological assays and assessed their suitability
for testing at single-animal and herd levels.
Methods
Bovine sera
Panel 1 (End point sera from B237 trial)
Thirty Zebu cattle were experimentally infected with
MmmSC B237, a strain isolated from an outbreak in
Thika, Kenya in 1997, as described previously [18]. The
animals were observed for up to 47 days (see Table 1),
and sera were collected during post mortem examina-
tion. Re-isolation of the agent was conducted and patho-
logical findings were specified in 15 animals (505, 506,
509, 513, 515, 519, 520, 522, 525, 527, 532, 539, 542,
543, and 544). Three negative cattle sera originated
from the animal facility of FLI Jena, Germany. Positive
control serum for the in-house CFT (reference serum
no. 315) and positive control serum for the IBT were
kindly provided by J. Regalla, LNIV Lisbon, Portugal.
Panel 2 (Sera from short-term Afadé trial)
The animals were experimentally infected with MmmSC,
strain Afadé, a strain isolated from an outbreak in North-
ern Cameroon in 1968 (kindly provided by Joachim Frey,
Table 1 Results of the B237 infection trial (Panel 1): Serological testing, re-isolation of MmmSC and pathological
findings from challenged cattle*
Animal-No. in-house CFT CIRAD CFT cELISA IBT Re-isolation Days after
infection at
slaughter
Lung lesions (size)
Titer Result Titer Result Inhibition [%] Result
505 0 - 0 - 28.7 - + yes 44 RC (9 cm)
506 0 - 0 - 34.0 - - yes 47 no lesion
509 0 - 10 + 62.3 + + yes 29 whole left side with consolidation
513 640 + 160 + 41.6 amb + yes 29 whole lung with consolidation
515 5 - 0 - 29.1 - + yes 44 no lesion
519 160 + 80 + 70.1 + + yes 47 RC and RD (9 cm each)
520 0 - 0 - 20.4 - amb no 47 no lesion
522 160 + 40 + 56.7 + + yes 47 whole left side with consolidation
525 160 + 40 + 51.2 + + yes 29 whole lung
527 320 + 80 + 61.6 + + yes 44 RA (5 cm)
532 0 - 0 - 46.7 amb - yes 47 fibrous adhesions
539 0 - 0 - 19.5 - amb. yes 47 no lesion
542 1280 + 640 + 42.5 amb + yes 29 RA and RC (9 cm each)
543 160 + 80 + 54.0 + + yes 44 RA and RC (9 cm each)
544 0 - 0 - 32.1 - + yes 44 no lesion
* All animals that were examined pathologically have been included (15/30 animals).
RA = right apical lobe, RC = right cadiac, RD = right diaphragmatic, amb = ambiguous (aberration from standard band pattern).
The CFT titre is given as the inverse of the highest dilution yielding 100% inhibition of haemolysis.
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intrabronchially with 50 ml of fresh MmmSC broth cul-
ture (2.5 × 10
10 colony forming units per animal), fol-
lowed by 20 ml of liquid 1.5% agar solution and 30 ml
phosphate-buffered saline. Sera were taken periodically
every 3 to 4 days from the day before infection (-1 dpi)
until necropsy, i.e. up to 30 dpi, from 20 Boran cattle
(BD091-102, BD105-107, BD111, BD115, BD116, BD118,
BD119). Positive and negative control sera were the same
as in Panel 1. Infection mode, sampling scheme, clinical
symptoms and pathological observations have been
described elsewhere [18,19].
Panel 3 (Sera from long-term Afadé trial)
To obtain samples from the late and chronic stages of
the disease, sera were taken periodically on a weekly
basis from 7 experimentally infected Boran cattle
(BD103, BD104, BD108, BD109, BD112, BD114, and
BD117) over a time period of approximately 8 months
to obtain samples from the late and chronic stages of
the disease. Infection mode and challenge strain were
the same as in Panel 2.
Tissue samples
Lung tissue samples were collected upon necropsy and
used for examination by culture and PCR [18,19]. Lungs
were inspected for lesions and, where possible, material
from these areas was excised for pathogen detection.
The animal experiments mentioned in this paper were
conducted in strict accordance with Kenyan legislation
on animal experimentation and were approved by the
Institutional Animal Care and Use Committee (IACUC
reference no. 2008.08). ILRI has been voluntarily comply-
ing with the United Kingdom’s Animals Act 1986, which
contains guidelines and codes of practice for housing and
care of animals used in scientific procedures.
Complement fixation tests
The protocols of the two CFTs used in this study were
largely identical, but notably differed in the type of anti-
gen used and the conditions of the antigen-binding step.
a) The in-house CFT was carried out in microplate for-
mat as recommended by the OIE for detection of antibo-
dies to MmmSC. Phenol-inactivated whole-cell antigen
o ft h et y p es t r a i nMmmSC PG1, which was previously
checkerboard titrated, was used as antigen at a concen-
tration of 2 complement fixing units. Other reagents for
the in-house CFT complement, i.e. haemolytic serum,
veronal buffer and sheep red blood cells, were obtained
from Virion-Serion (Würzburg, Germany). Antigen bind-
ing was allowed during overnight incubation at 4°C.
b) The CIRAD CFT (CIRAD, Montpellier, France),
was conducted according to the manufacturer’si n s t r u c -
tions. The kit included all reagents except veronal
buffer, sheep red blood cells and negative control serum
(purchased from Virion-Serion). The incubation time
for antigen binding at 37°C was 30 min.
All sera used were inactivated at 56°C for 30 min and
diluted in the range of 1:5 to 1:2560. The highest dilu-
tions of sera producing 100% haemolysis inhibition of
sheep red blood cells were taken as end points of dilu-
tions to be examined, and CFT titres were given as reci-
procals of these dilutions.
CFT readings were scored according the OIE manual
[2], i.e. positive in the case of 100% inhibition of haemo-
lysis at a serum dilution of 1:10 or greater; ambiguous
at 25, 50 or 75% inhibition at 1:10 serum dilution, and
negative with absent haemolysis or haemolysis at 1:5
serum dilution.
Enzyme immunoassay
The CBPP serum competitive ELISA (IDEXX, Institute
Pourquier, Montpellier, France) was used for screening
the sera. The test is based on the paper by Le Goff and
Thiaucourt [20] and uses a monoclonal anti-MmmSC
antibody, as well as microplates coated with MmmSC
lysate. The ELISA was performed according to the
instructions of the manufacturer. Optical densities (OD)
were measured at 450 nm using the photometer Spectra
Fluor (Tecan, Crailsheim, Germany). The percentage
inhibition value (INH%) for each serum sample was cal-
culated using the formula:
INH% = (ODmab − ODsample)/(ODmab − ODconjugate) × 100%,
ODmab = Control only with monoclonal antibody and without serum (0% inhibition)
ODsample = OD of the serum sample
ODconjugate = Control without monoclonal antibody and serum (100% inhibition).
The cut-off for positive samples was at INH% of 50%.
Sera with an inhibition value between 40% and 50%
were considered doubtful. All sera were examined in
duplicate.
Immunoblotting test
The IBT was performed according to Regalla et al. [5]
and the OIE manual [2] with minor modifications. SDS-
PAGE (7.5% polyacrylamide) separated proteins of refer-
ence strain MmmSC PG1 and strain Afadé were trans-
ferred onto nitrocellulose membrane (Whatman, Dassel,
Germany). The BenchMark Protein Ladder 10-220 kDa
(Invitrogen, Karlsruhe, Germany) was used as molecular
weight marker. To control the efficiency of protein
transfer, a reversible protein staining step using Ponceau
S (Sigma-Aldrich, Taufkirchen, Germany) was included.
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serum dilutions or control serum, respectively. Reactive
bands were visualised using alkaline phosphatase-conju-
gated recombinant protein A/G (Pierce, Bonn, Ger-
many) and substrate BCIP/NTB (5-bromo-4-chloro-3-
indolyl phosphate combined with nitrotetrazolium blue
chloride, Sigma-Aldrich). Positive sera were expected to
s h o was p e c i f i cp a t t e r nt h a tincluded reactive bands at
110, 98, 95, 60/62, and 48 kDa. IBT patterns of sera
were scored ambiguous in case that either the specific
band of 98 kDa was missing or other specific bands
were weak.
Bacteriological evaluation and identification
Isolation and cultivation of Mycoplasma strains from tis-
sue samples were performed using standard methodol-
ogy [21]. Lung tissue samples collected during post
mortem from margins of sequestra or regions of necro-
sis were inoculated into modified Hayflick medium [21]
and incubated at 37°C for 3 to 4 days. Identification of
MmmSC from these cultures was done using PCR (see
next paragraph).
PCR
Mycoplasma cultures and tissue samples of Panel 2 and
3 animals were examined using a MmmSC-specific PCR
assay described previously [6,22].
Statistical evaluation
The kappa agreement test was conducted [23] to com-
pare the concordance between individual tests. For each
animal, the mean of all the measurements was calcu-
lated for each individual assay and an animal was classi-
fied positive based on the set criterion. The proportion
of positive animals was computed as a percentage of the
test positives against the total number tested.
Results
Examination of end point sera from the B237 trial (Panel
1)
Of the 30 animals challenged, 25 (83.3%) displayed a
specific antibody response detected by at least one of
the serological tests, whereas all sera from non-infected
animals remained negative. A positive test result of sera
to all the four tests was observed in 12 (40%) cases. Re-
isolation of the challenge strain was attempted in 15
cases, of which 14 were successful [18]. The findings
obtained from these animals are summarised in Table 1.
Notably, the infective strain was also re-isolated from
four animals without lesions. The lesion-free subgroup
tested negative both in cELISA and CFTs (animals 506,
515, 520, 539, 544), IBT was either positive (animals 515
and 544), ambiguous (animals 520 and 539; Table 1), or
negative (animal 506). Regarding all infected animals,
the number of positive results in IBT was higher than in
the other methods.
Examination of sera from the short-term Afadé trial
(Panel 2)
Serological testing using both CFTs confirmed success-
ful infection of all animals (see Additional File 1: Results
of in-house CFT vs. CIRAD CFT from sera of Panel 2).
T h et i m ec o u r s eo fs p e c i f i ca n t i b o d yp r o d u c t i o ni na l l
20 animals is shown in Figure 1. The humoral response
patterns as detected by CFT can be classified into three
categories, i) early high responders (BD091, BD092,
BD093, BD097, BD098, BD099, BD107, BD111, BD115,
BD118, BD119), ii) late high responders (BD094, BD095,
BD116), and iii) low responders (BD096, BD100, BD101,
BD102, BD105, BD106). CFT titres of early high respon-
ders emerged at 6 dpi in the case of animal BD119 and
at 9 dpi in the other animals (Figure 1A). For late high
responders, a pronounced rise around 13 dpi was char-
acteristic (Figure 1B).
Figure 1 also reveals that the course of the humoral
responses of Panel 2 cattle were not completely concur-
rent in CFT and cELISA. The increase of the cELISA
titres was seen after day 6 post infection (see Additional
File 2: Examination of Panel 2 sera using cELISA), with
the exception of animal BD091 (beginning at 6 dpi,
Figure 1A; see also below). In the subgroup of low
responders, the rise in cELISA titres was generally weak,
with animals BD101, BD102, BD105, and BD106
remaining below the cut-off level throughout the trial
(as did animals BD092, BD097, BD111, and BD118 of
the early high responder group). Nevertheless, the
cELISA-negative animals mentioned showed positive
results in both CFTs (see Additional File 1: Results of
in-house CFT vs. CIRAD CFT from sera of Panel 2). In
addition, the cELISA-negative animals BD097 and
BD101 exhibited characteristic bands in the IBT. Figure 2
shows immunoblot patterns of four selected animals of
Panel 2. While the IBT results were largely comparable
to CFT findings, this test also detected emerging specific
antibodies to MmmSC at earlier time points than
cELISA (Table 2).
Seropositivitiy of Panel 2 sera in cELISA and CFT did
not always correlate with clinical symptoms and patho-
morphological signs. Conversely, however, negative or
weakly positive readings in cELISA and CFT correlated
with the absence of clinical signs or mild symptoms.
Patho-morphological lesions typical for MmmSC infec-
tions were observed in all animals of the short-term
Afadé trial except animal BD102. Four animals died or
had to be sacrificed prematurely, i.e. at 16 dpi (BD091,
BD097, BD118) or at 20 dpi (BD098). This subgroup
belonged to early high responders showing severe clini-
cal symptoms (high temperature, cough, dyspnoea), as
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Page 4 of 11Figure 1 Comparison of CIRAD CFT and cELISA-based curves showing the antibody response of animals from Panel 2. Animals from the
Short-term Afadé trial were characterised by CFT (bars) and cELISA (curves). Horizontal lines represent the cut-off values of CFT (dilution 1:10,
100% inhibition of haemolysis) and cELISA (50% inhibition), respectively. The assignment of letters and symbols to the respective animals is given
in the right-hand column. A: Early high responders (according to CFT), B: Late high responders, C: Low responders. Missing bars at later time
points indicate that the respective animal died or had to be removed prematurely.
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and lymph node tissues.
Examination of sera from the long-term Afadé trial (Panel 3)
Sera from all 7 animals showed positive reactions with
all four methods used. In a typ i c a lt i m ec o u r s e( F i g u r e
3), detectable CFT titres emerged in week 2 p.i. and
decreased steadily from weeks 5-8. At the end of this
infection trial, i.e. 34 weeks p.i., CFT titres ranged
between 1:10 to 1:20 for the in-house CFT (see Addi-
tional File 3: Examination of Panel 3 sera using in-house
CFT), and between 1:5 and 1:160 for the CIRAD CFT
(see Additional File 4: Examination of Panel 3 sera using
CIRAD CFT). Since sera were collected only on a
weekly basis, classification into responder groups as in
Panel 2 animals was not feasible. Notably, animal
BD117 differed from the other animals by responding
one week later in both CFTs.
Test results of the cELISA showed a rise in titres from
week 3 to 4 p.i., with levels either remaining positive
until to the end of the trial (Figure 3) or slowly decreas-
ing to reach the cut-off value of 50% inhibition (see
Additional File 5: Examination of Panel 3 sera using
cELISA).
The time course of specific antibody response as mon-
itored by IBT is shown in Figure 4. Animal BD103 was
somewhat peculiar as the specific antigenic band of 60-
62 kDa faded after week 10 p.i. The same band disap-
peared in the reaction of animal BD117 after week 10,
whereas animal BD104 maintained the entire specific
banding pattern until the end at week 34 (data not
shown).
Figure 2 Immunoblotting analysis of sera from selected animals of Panel 2 (Short-term Afadé trial). Nitrocellulose strips carrying SDS-
PAGE separated whole-cell antigen of MmmSC strain Afadé were incubated with a 1:100 dilution of the serum, and reactive bands were
visualised using AP-conjugated anti-bovine IgG and BCIP/NTB. A: animal BD093, B: animal BD099, C: animal BD101, D: animal BD097. Black arrows
indicate additional bands close to MmmSC-specific bands that are not observed with all sera (B, C, and D) and a prominent additional band,
which occurred only on positive strips of animal BD093 (A). Molecular weights (in kDa) of specific bands that have been recommended for
identification of the infection are indicated. NC = negative control serum, PC = positive control serum.
Schubert et al. BMC Veterinary Research 2011, 7:72
http://www.biomedcentral.com/1746-6148/7/72
Page 6 of 11General comparison between the serological methods
All test results of the four assays from sera of Panels 1
and 2 have been compared and summarised in Table 3.
The compilation shows that general agreement among
the results of all tests used was poor. As confirmed by
kappa agreement testing, the results of in-house and
CIRAD CFTs were always close to each other, when
taking into account the inherent systematic error of two
dilution titres (see Table 1, see Additional File 1: Results
of in-house CFT vs. CIRAD CFT from sera of Panel 2).
The number of positive findings by CFTs was generally
higher than those from cELISA, which implies a delay
in the detection of the onset of antibody production by
t h el a t t e r( s e eT a b l e2 ,F i g u r e1 ) .T h es e n s i t i v i t yo ft h e
IBT proved intermediate between cELISA (less sensitive)
and CFT (more sensitive), when consecutively collected
sera were examined (Panel 2).
Discussion
The remarkable degree of variation in the humoral
immune response displayed by the animals of the pre-
sent study indicates a high complexity of host-pathogen
interactions during MmmSC infection, which can lead
to acute, sub-acute to chronic or symptomless courses
of disease [17]. On the one hand, the immune status of
the individual animal seems to play a role in the time
course and level of specific antibody production. Naïve
animals are assumed to react in a different fashion than
re-infected cattle exhibiting an anamnestic response,
and symptomless carriers can exhibit low antibody levels
in the absence of intense host pathogen interactions.
Inter-animal differences in the cellular immune response
[18,19], which have not been addressed in the present
study, may also add to the overall diversity observed.
On the other hand, the pathogen has been shown to
possess a genetically determined machinery for surface
antigen variation [24,25], which enables it to evade the
host immune response by selecting modified phenotypes
that cannot be challenged by cognate antibodies.
Depending on the efficiency of the individual host
defence, the progress of MmmSC infection can be
expected to vary from animal to animal.
The authors wish to emphasise that the present com-
parative analysis of diagnostic tests is referring to the
individual animal level, which is a limitation because the
data cannot be simply extrapolated to herd level. While
currently available serological tests are generally suitable
for herd diagnosis, the present findings highlight serious
limitations of these tests at the individual animal level,
which have to be taken into account when field studies
are conducted.
CFT titres do not represent the whole spectrum of
specific antibodies present in the infected animal, nor
are they long lasting. The half-life of CFT antibody titres
Table 2 Comparison of the specific antibody response of
selected* cattle from the short-term Afadé trial (Panel 2)
using four serological tests
Animal Time of serum
collecion (dpi)
In-house
CFT
CIRAD
CFT
cELISA IBT
-1 - - - -
2- - n d n d
6- - - -
9 + + - amb
BD 093 13 + + amb +
16 + + amb +
20 + + + +
23 + + + +
27 + + + +
-1 - - - -
2- - - -
BD 097 6 - - - -
9 + + - amb
13 + + - +
16 + + - +
-1 - - - -
2- - - -
6- - - -
9+ + - -
BD 099 13 + + amb nd
16 + + amb +
20 + + + +
23 + + + +
27 + + + +
-1 - - -
2- - - -
6- - - -
9- - - -
BD 101 13 - - - nd
16 + + - amb
20 + + - +
23 + + - +
27 + + - +
-1 - - - nd
2- - - n d
6- - - n d
9- + - n d
BD 105 13 - + - nd
16 - + - nd
20 - + - nd
23 - + - nd
27 + + amb nd
-1 - - - nd
2- - - n d
BD 118 6 - - - nd
9+ + - n d
13 + + - nd
16 + + amb nd
* animals surviving at least until 16 dpi, amb = ambiguous, nd = not done
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Notably, our own data indeed show a steep decline in
these titres, beginning between weeks 3 and 6 p.i.
(Figure 3, see Additional File 3: Examination of Panel 3
sera using in-house CFT and Additional File 4:
Examination of Panel 3 sera using CIRAD CFT). Such a
drop in CFT titres was also observed in the contact
challenge study of Niang and co-workers [17], albeit sig-
nificantly delayed (from week 16 to 36) as the precise
time point of each individual infection remained elusive
Figure 3 Comparison of CIRAD CFT and cELISA based curves showing the specific antibody response of animal BD114. CFT titres of
animal BD114 (Panel 3, long-term Afadé trial) are given as the inverse value of the highest dilution yielding 100% inhibition of haemolysis.
Please note, that the CFTs cut-off is at 10 (dilution of the serum 1:10).
Figure 4 Immunoblotting analysis of animal BD103 (Panel 3, long-term Afadé trial). Western blotted nitrocellulose strips of MmmSC strain
Afadé were incubated with 1:100 dilutions of sera collected weekly from challenged animal BD103 (Panel 3) and processed as described in
Materials and Methods. The white arrow indicates an additional band close to the specific 48-kDa band, and black arrows indicate bands fading
after week 15 p.i. Molecular weights (in kDa) of specific bands that have been recommended for identification of the infection are indicated. NC
= negative control serum, PC = positive control serum.
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tions imply that field studies based solely on CFT are
prone to miss individual animals at the later stages of
infection.
While the differences between the two CFTs used
were marginal, the relative diagnostic sen-sitivity of both
tests compared to culture was 50.0% (in-house CFT)
and 57.1% (CIRAD CFT) with Panel 1 samples, which is
in line with data of other authors [27]. The consistently
observed divergence between the results of CFT and
cELISA (Table 2, Figure 3) is probably a consequence of
the different immunoglobulin classes covered by each
method. Thus, IgG class antibodies have a greater affi-
nity in the cELISA, while IgG2 subclass antibodies are
unable to fixate complement used in the CFT. More-
over, IgM class antibodies, which are characteristic for
early infection, are easier to detect by CFT [28,29]. This
can explain the earlier detection of antibodies by CFT as
observed in the present study and elsewhere [20,30].
Furthermore, the present finding that IgG antibody
levels from cELISA remained at a high level for a pro-
longed period is in agreement with the study by Niang
and co-workers [17], where the kinetics of different anti-
body isotypes was investigated.
It is important to note that the present cELISA was
given a relatively high cut-off in order to maximise speci-
ficity, which in turn diminishes the test’s sensitivity [31].
In fact, the present evidence suggests that there is some
room for lowering the cut-off without loss of specificity.
However, this has to be confirmed by further studies
involving more field sera from cattle herds having CBPP
and/or other mycoplasma infections. We hypothesise
that another way to improve the test’s performance
includes the use of specific peptides [32] or recombinant
MmmSC proteins [16,33] instead of whole-cell antigen.
The IBT has been described as being more sensitive
and specific than CFT [13], which has been confirmed
by the present data (Table 1). Thus, the IBT showed
specific reaction patterns for sera tested negative in CFT
and cELISA (animals 515, 520, 539, 544, 546). The test’s
high specificity is based on the reaction to five different
antigens, i.e. 110, 98, 95, 60/62, and 48 kDa proteins,
which must be recognised by their specific antibodies in
order to identify a positive serum [2]. However, we
observed some problems with the test’s reproducibility
and potential for standardisation, as immunoblot reac-
tion patterns are complex and individual bands may be
difficult to identify when non-specific bands from cross-
reactions with other bacteria are interfering. Cross-reac-
tions with closely related Mycoplasma (M.) species of
the “mycoides cluster” seem to be less important here,
because they are rarely encountered in cattle, but other
mycoplasmas, such as M. bovis and M. bovigenitalium,
may play a role [13,31].
Culture of MmmSC from affected lung tissue was
included to underpin our serological findings. While ser-
opositive animals always showed clinical symptoms of
CBPP that were confirmed by pathology, the presence of
lung lesions was no guarantee for successful re-isolation
of the challenge strain (Panel 2, data not shown). The
findings of the present study also suggest that re-isolation
was seriously hampered at the late and chronic stages of
infection, i.e. isolation of MmmSC did not succeed from
tissue samples of Panel 3 animals after 35 weeks p.i. The
absence of a strict correlation was particularly evident
with animal 506 (Panel 1, Table 1), where all serological
tests were negative (and pathological signs were missing)
despite successful re-isolation of the pathogen.
Conclusions
The present study has revealed three distinct seroconver-
sion patterns among MmmSC-infected animals, i) early
high responders, ii) late high responders, and iii) low
responders. This variability raises questions as to the choice
and suitability of current serological tests for single-animal
diagnosis. While valid at the herd level, individual test
results can be misleading and negative serological findings
should be interpreted with particular caution.
Table 3 Examination of Panel 1 and 2 sera: Comparison of all serological tests*
Assays compared Number (percentage) of animals reacting similarly in the tests compared
30 sera of Panel 1 Selection of 30 sera of Panel 2 (including IBT) All 178 sera of Panel 2
(without IBT)
cELISA and in-house CFT 21 (70%), ĸ = 0,46
c 18 (60%), ĸ = 0,33
d 114 (70%), ĸ = 0,43
c
cELISA and CIRAD CFT 23 (77%), ĸ = 0,58
c 18 (60%), ĸ = 0,33
d 108 (62%), ĸ = 0,38
d
In-house CFT and CIRAD CFT 27 (90%), ĸ = 0,79
a 30 (100%), ĸ = 1,00
a 161 (90%), ĸ = 0,80
a
In-house CFT and IBT 21 (70%), ĸ = 0,39
d 26 (87%), ĸ = 0,33
d
CIRAD CFT and IBT 21 (70%), ĸ = 0,39
d 26 (87%), ĸ = 0,33
d
cELISA and IBT 17 (57%), ĸ = 0,23
d 19 (63%), ĸ = 0,38
d
In-house CFT, CIRAD CFT and cELISA 21(70%) 18 (60%) 102 (59%)
In-house CFT, CIRAD CFT, cELISA and IBT 15 (45%) 18 (60%)
* Kappa agreement testing [23] was additionally conducted. According to standard criteria, the concordance between two tests compared is classifieda s
a very
good (1-0.76),
b good (0.75-0.61),
c acceptable (0.6-0.4),
d poor (< 0.4).
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Page 9 of 11Two factors account for the lack of sensitivity of sero-
logical tests at the single-animal level, i) titres of specific
antibodies at an early stage of infection and in chronic
carriers can be very low, and ii) high variability in anti-
g e ne x p r e s s i o nb yMmmSC in vivo, where not all rele-
vant proteins are expressed at a given point in time
[24,34]. We suggest that diagnostic testing should com-
prise both CFT and cELISA, particularly in countries
declared free of CBPP.
Unlike CFT and ELISA, the IBT requires experienced
and well-trained laboratory personnel and is not suitable
for use in routine laboratories. To improve reproducibil-
ity, we recommend i) the use of 7.5% acrylamide gels
instead of gradient gels as prescribed in the OIE manual
[2], and ii) the use of the same antigen in all labora-
tories, i.e. MmmSC strain Afadé. We propose that the
methodology in [2] be accordingly revised and supple-
mented with more detailed instructions to address the
above mentioned problems (see Additional File 6: Pro-
posal for modification of the current OIE protocol for
IBT), so that IBT can be used as an additional test in
the case of ambiguous CFT and/or cELISA results.
Additional material
Additional file 1: Results of in-house CFT vs. CIRAD CFT from sera
of Panel 2. Humoral immune response of animals from Panel 2 (Short-
term Afadé trial) as characterised by in-house CFT and CIRAD CFT. End-
point titres of both CFTs are shown at different time points of infection.
Additional file 2: Examination of Panel 2 sera using cELISA. Humoral
immune response of animals from Panel 2 (Short-term Afadé trial)
characterised by cELISA. The percentage inhibition value (INH%) for each
serum sample was calculated using the formula: INH% = (ODmab -
ODsample)/(ODmab -O D conjugate) × 100%, ODmab = Control only with
monoclonal antibody and without serum (0% inhibition), ODsample =O D
of the serum sample, ODconjugate = Control without monoclonal antibody
and serum (100% inhibition). The cut-off for positive samples was set at
INH% of 50%. Sera with an inhibition value between 40% and 50% were
considered doubtful. All sera were examined in duplicate. ND = not
done.
Additional file 3: Examination of Panel 3 sera using in-house CFT.
Examination of the 7 sera from the long-term Afadé trial (Panel 3) using
in-house CFT. End-point titres of the CFT were shown until 34 weeks p.i.
Additional file 4: Examination of Panel 3 sera using CIRAD CFT.
Examination of the 7 sera from the long-term Afadé trial (Panel 3) using
CIRAD CFT. End-point titres of the CFT were shown until 34 weeks p.i.
Additional file 5: Examination of Panel 3 sera using cELISA.
Examination of the 7 sera from the long-term Afadé trial (Panel 3) using
cELISA. Data of the cELISA were given in percentage inhibition and
shown until 34 weeks p.i.
Additional file 6: Proposal for modification of the current OIE
protocol for IBT. To improve the reproducibility of IBT results, the
authors of the present paper recommend two modifications to the
protocol of the OIE Manual.
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